Our findings suggest that PRC2-mediated suppression under homeostatic and inflammatory conditions limits ASC differentiation and that this can be therapeutically exploited through inhibition of Ezh2 to amplify protective antibody responses in various human immune-deficient disorders. Here, EZH2 is linked to inborn error of immunity.